P/B
2,3
Prelude Therapeutics
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
$309.5M
Market Cap • 10/8/2026
2016
(10 years)
Founded
2020
(6 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
13,8
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
1,7
EPS
—
Market Cap
Market Cap
309,5M
EV
175,4M
EV/Revenue
7,8
EV/EBITDA
-2,7
EV/EBIT
-2,6
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-0,1%
Total Yield
-0,1%
Payout
0%
Retained Earnings
-707,4M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
309,6%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
16,3%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
-5,1%
CAGR Net Income 5Y
-6,4%
CAGR OCF 5Y
-12,1%
Leverage
N.D./EBITDA
2
Debt/Equity
0%
Current Ratio
4,1
Quick Ratio
4
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!